For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Annexon, Inc. (ANNX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Annexon, Inc. is a member of the Medical sector. This group includes 1051 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 differ ...

BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on April 12, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the ...

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board o ...

Company Summary - Annexon, Inc. (ANNX) closed at $6.17, reflecting a -0.96% change from the previous day's closing price, underperforming the S&P 500 which fell by 0.95% [1] - The stock has increased by 35.73% over the past month, outperforming the Medical sector's decline of 3.76% and the S&P 500's gain of 1.78% [1] - The upcoming earnings report is expected to show an EPS of -$0.32, representing a 38.46% increase compared to the same quarter last year [1] - Recent analyst forecast revisions for Annexon, Inc. are crucial as they indicate short-term business trends, with positive changes reflecting optimism about the company's profitability [1] Industry Summary - The Medical - Biomedical and Genetics industry is part of the broader Medical sector and currently holds a Zacks Industry Rank of 80, placing it in the top 32% of over 250 industries [2] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown that stocks rated 1 have delivered an average annual return of +25% since 1988 [2] - The top 50% rated industries outperform the bottom half by a factor of 2 to 1, indicating the importance of industry ranking in stock performance [3]

Investors might want to bet on Annexon, Inc. (ANNX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual inv ...

Shares of Annexon, Inc. (ANNX) have gained 20.1% over the past four weeks to close the last trading session at $7.17, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.42 indicates a potential upside of 101.1%.The mean estimate comprises six short-term price targets with a standard deviation of $8.04. While the lowest estimate of $8.50 indicates an 18.6% increase from the curr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39402 ANNEXON, INC. (Exact name of Registrant as specified in its Charter) Delaware 27-5414423 (State or other jurisdiction of incorp ...

Exhibit 99.1 Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024, a Global ShamControlled Trial Using Vision Preservation as Primary Outcome Measure Clinical Proof-of-Concept Data with ANX1502 Oral Inhibitor of the Classical Pathway Expected in Second Half of 2024 Rob ...

BRISBANE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 15, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). The new non-executive emplo ...

Investors are always looking for stocks that are poised to beat at earnings season and Annexon, Inc. (ANNX) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Annexon is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicat ...